Table 2.
Patient characteristics.
| All patients | Age<18 | Age≥18 | P value | |
|---|---|---|---|---|
| (n = 67) | (n = 25) | (n = 42) | ||
| Symptoms at onset | ||||
| Visual loss | 24 (35.8) | 9 (36.0) | 15 (35.7) | 0.981 |
| Paralysis | 16 (23.9) | 5 (20.0) | 11 (26.2) | 0.636 |
| Paresthesia | 19 (28.4) | 5 (20.0) | 14 (33.3) | 0.242 |
| Nausea/Vomiting | 7 (10.4) | 6 (24.0) | 1 (2.4) | 0.009* |
| Fever | 10 (14.9) | 5 (20.0) | 5 (11.9) | 0.368 |
| Headache | 10 (14.9) | 2 (8.0) | 8 (19.0) | 0.300 |
| Dizziness | 7 (10.4) | 1(4.0) | 6 (14.3) | 0.244 |
| Seizures | 12 (17.9) | 5 (20.0) | 7 (16.7) | 0.731 |
| Speech disorders | 2 (3.0) | 1 (4.0) | 1 (2.4) | 1.000 |
| Unsteady gait | 5 (7.5) | 4 (16.0) | 1 (2.4) | 0.061 |
| Disturbance of consciousness | 2 (3.0) | 1 (4.0) | 1 (2.4) | 1.000 |
| Disease spectrum | ||||
| Optic neuritis | 24 (35.8) | 9 (36.0) | 15 (35.7) | 0.981 |
| Transverse myelitis | 18 (26.9) | 9 (36.0) | 9 (21.4) | 0.193 |
| Acute disseminated encephalomyelitis | 11(16.4) | 10 (40.0) | 1 (2.4) | 0.000* |
| Brainstem syndrome | 11 (16.4) | 4 (16.0) | 7 (16.7) | 1.000 |
| Post polar syndrome | 7 (10.4) | 6 (24.0) | 1 (2.4) | 0.009* |
| Treatment | ||||
| Corticosteroid | 63 (94.0) | 25 (100) | 38 (90.5) | 0.112 |
| Intravenous immunoglobulin | 14 (20.9) | 7 (28.0) | 7 (16.7) | 0.270 |
| Immunosuppressant | ||||
| Azathioprine | 4 (6.0) | 0 | 4 (9.5) | 0.289 |
| Mycophenolate mofetil | 3 (4.5) | 1 (4.0) | 2 (4.8) | 1.000 |
| Methotrexate | 1 (1.4) | 1 (4.0) | 0 | 0.373 |
| Initial EDSS | 4 (2–6) | 4 (3–4.75) | 4 (2–6) | 0.974 |
| Discharge EDSS | 2 (1–4) | 1.5 (1–3) | 2 (1–4) | 0.351 |
| Follow-up EDSS | 1.5 (1–2) | 1 (1–2) | 1.5 (1–2) | 0.340 |
| Follow-up interval (months) | 7 (5–15) | 6 (3.5–8.5) | 8 (5.375–16.75) | 0.109 |
| Relapse | 14 (20.9) | 6 (24.0) | 8 (19.0) | 0.630 |
Data are presented as mean ± standard deviation, number (percentage), or median (interquartile range).
EDSS, expanded disability status scale scores.
*P < 0.05.